Is Travere Therapeutics Stock a Good Investment?
Travere Therapeutics Investment Advice | TVTX |
- Examine Travere Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Travere Therapeutics' leadership team and their track record. Good management can help Travere Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Travere Therapeutics' business and its evolving consumer preferences.
- Compare Travere Therapeutics' performance and market position to its competitors. Analyze how Travere Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Travere Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Travere Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Travere Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Travere Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Travere Therapeutics Stock
Researching Travere Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The book value of Travere Therapeutics was at this time reported as 0.97. The company recorded a loss per share of 5.41. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011.
To determine if Travere Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Travere Therapeutics' research are outlined below:
| Travere Therapeutics generated a negative expected return over the last 90 days | |
| Travere Therapeutics has high historical volatility and very poor performance | |
| Travere Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (376.33 M) with loss before overhead, payroll, taxes, and interest of (31.35 M). | |
| Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Travere Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Travere Therapeutics First Quarter 2024 Earnings Misses Expectations |
Travere Therapeutics Quarterly Good Will |
|
Travere Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Travere Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Travere Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Travere Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Travere Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-04 | 2017-03-31 | -0.26 | -0.29 | -0.03 | 11 | ||
2017-03-01 | 2016-12-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2020-11-05 | 2020-09-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2017-08-09 | 2017-06-30 | -0.21 | -0.34 | -0.13 | 61 | ||
2016-08-04 | 2016-06-30 | -0.23 | -0.37 | -0.14 | 60 | ||
2016-02-25 | 2015-12-31 | -0.21 | -0.07 | 0.14 | 66 | ||
2022-01-10 | 2021-12-31 | -0.68 | -0.84 | -0.16 | 23 | ||
2022-08-04 | 2022-06-30 | -0.88 | -1.05 | -0.17 | 19 |
Know Travere Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Travere Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Travere Therapeutics backward and forwards among themselves. Travere Therapeutics' institutional investor refers to the entity that pools money to purchase Travere Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2023-12-31 | 2.4 M | Kynam Capital Management, Lp | 2023-12-31 | 2 M | Bank Of America Corp | 2023-12-31 | 1.6 M | Geode Capital Management, Llc | 2023-12-31 | 1.5 M | Finepoint Capital Lp | 2023-12-31 | 1.4 M | Millennium Management Llc | 2023-12-31 | 1.3 M | Farallon Capital Management, L.l.c. | 2023-12-31 | 1.1 M | Emerald Advisers, Llc | 2023-12-31 | 1 M | Parkman Healthcare Partners Llc | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 7.9 M | Armistice Capital, Llc | 2023-12-31 | 7.4 M |
Travere Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 479.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Travere Therapeutics's market, we take the total number of its shares issued and multiply it by Travere Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Travere Therapeutics' profitablity analysis
Travere Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Travere Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Travere Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Travere Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Travere Therapeutics' profitability requires more research than a typical breakdown of Travere Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.62) | (0.59) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.55) | (0.53) |
Determining Travere Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Travere Therapeutics is a good buy. For example, gross profit margin measures Travere Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Travere Therapeutics' profitability and make more informed investment decisions.
The data published in Travere Therapeutics' official financial statements usually reflect Travere Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Travere Therapeutics. For example, before you start analyzing numbers published by Travere accountants, it's critical to develop an understanding of what Travere Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Travere Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Travere Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Travere Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Travere Therapeutics. Please utilize our Beneish M Score to check the likelihood of Travere Therapeutics' management manipulating its earnings.
Evaluate Travere Therapeutics' management efficiency
Travere Therapeutics has return on total asset (ROA) of (0.3553) % which means that it has lost $0.3553 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1589) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to rise to -0.59 in 2024. At this time, Travere Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 20.3 M in 2024, whereas Total Assets are likely to drop slightly above 461.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.70 | 2.66 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.30 | 1.36 | |
| Enterprise Value Over EBITDA | (3.06) | (3.21) | |
| Price Book Value Ratio | 3.32 | 3.16 | |
| Enterprise Value Multiple | (3.06) | (3.21) | |
| Price Fair Value | 3.32 | 3.16 | |
| Enterprise Value | 1 B | 646.3 M |
The analysis of Travere Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Travere Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Travere Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.692 |
Basic technical analysis of Travere Stock
As of the 14th of May 2024, Travere Therapeutics has the Coefficient Of Variation of (1,114), risk adjusted performance of (0.05), and Variance of 14.12. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Travere Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Travere Therapeutics, which can be compared to its competition. Please validate Travere Therapeutics variance, as well as the relationship between the maximum drawdown and skewness to decide if Travere Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 6.7 per share. Given that Travere Therapeutics has information ratio of (0.11), we advise you to double-check Travere Therapeutics's current market performance to make sure the company can sustain itself at a future point.Travere Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Travere Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Travere Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Travere Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cline Christopher R. over a month ago Disposition of tradable shares by Cline Christopher R. of Travere Therapeutics at 6.74 subject to Rule 16b-3 | ||
Cline Christopher R. over a month ago Acquisition by Cline Christopher R. of 25000 shares of Travere Therapeutics subject to Rule 16b-3 | ||
Squarer Ron over six months ago Acquisition by Squarer Ron of 4500 shares of Travere Therapeutics subject to Rule 16b-3 | ||
William Rote over a year ago Sale by William Rote of 825 shares of Travere Therapeutics | ||
William Rote over a year ago Acquisition by William Rote of 20250 shares of Travere Therapeutics subject to Rule 16b-3 |
Understand Travere Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Travere Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.05 | |||
| Mean Deviation | 3.02 | |||
| Coefficient Of Variation | (1,114) | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.12 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | 1.04 | |||
| Maximum Drawdown | 14.83 | |||
| Value At Risk | (6.26) | |||
| Potential Upside | 5.16 | |||
| Skewness | (0.09) | |||
| Kurtosis | (0.19) |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.05 | |||
| Mean Deviation | 3.02 | |||
| Coefficient Of Variation | (1,114) | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.12 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | 1.04 | |||
| Maximum Drawdown | 14.83 | |||
| Value At Risk | (6.26) | |||
| Potential Upside | 5.16 | |||
| Skewness | (0.09) | |||
| Kurtosis | (0.19) |
Consider Travere Therapeutics' intraday indicators
Travere Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Travere Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 44858.09 | |||
| Daily Balance Of Power | 1.333333 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 6.59 | |||
| Day Typical Price | 6.62 | |||
| Price Action Indicator | 0.3 | |||
| Period Momentum Indicator | 0.36 |
Travere Therapeutics Corporate Filings
8K | 13th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 10th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 1st of May 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 27th of March 2024 Other Reports | ViewVerify |
Travere Stock media impact
Far too much social signal, news, headlines, and media speculation about Travere Therapeutics that are available to investors today. That information is available publicly through Travere media outlets and privately through word of mouth or via Travere internal channels. However, regardless of the origin, that massive amount of Travere data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Travere Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Travere Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Travere Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Travere Therapeutics alpha.
Travere Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Travere Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Travere Therapeutics Corporate Management
Elected by the shareholders, the Travere Therapeutics' board of directors comprises two types of representatives: Travere Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Travere. The board's role is to monitor Travere Therapeutics' management team and ensure that shareholders' interests are well served. Travere Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Travere Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD | General VP | Profile | |
| Elizabeth Reed | General VP | Profile | |
| William Rote | Senior Development | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Angela Giannantonio | Senior Resources | Profile | |
| Jula MD | Chief Officer | Profile | |
| Casey Logan | Chief Officer | Profile |
How to buy Travere Stock?
To provide specific investment advice or recommendations on Travere Therapeutics stock, we recommend investors consider the following general factors when evaluating Travere Therapeutics. This will help you to make an informed decision on whether to include Travere Therapeutics in one of your diversified portfolios:- Examine Travere Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Travere Therapeutics' leadership team and their track record. Good management can help Travere Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Travere Therapeutics' business and its evolving consumer preferences.
- Compare Travere Therapeutics' performance and market position to its competitors. Analyze how Travere Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Travere Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Travere Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Travere Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Travere Therapeutics is a good investment.
Already Invested in Travere Therapeutics?
The danger of trading Travere Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Travere Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Travere Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Travere Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Travere Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Travere Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Travere Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Travere Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Travere Stock analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Travere Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 2.035 | Quarterly Revenue Growth 0.339 | Return On Assets (0.36) | Return On Equity (3.16) |
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Travere Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.